TITLE

Call for Elan to publish Alzheimer's trial details

AUTHOR(S)
Bishop, Glenda M.; Robinson, Stephen R.; Smith, Mark A.; Perry, George; Atwood, Craig S.
PUB. DATE
April 2002
SOURCE
Nature;4/18/2002, Vol. 416 Issue 6882, p677
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the request of the authors to Elan Pharmaceuticals to publish the details of the trial of the treatment of Alzheimer's disease. Release of Elan of details of their medical condition; Withdrawal of Elan of AN-1792 vaccine from human trials; Lack of obligation of Elan to report the results of the AN-1792 trials.
ACCESSION #
7503152

 

Related Articles

  • J&J Deal Lifts Overhang on Elan Stock; Investors Cautious. Sheridan, Cormac // BioWorld International;7/8/2009, Vol. 14 Issue 27, p1 

    The article reports on the U.S.$1.5 billion partnership deal signed by Elan Corp. PLC with Johnson & Johnson covering its Alzheimer's disease immunotherapy program. The growth of Elan's drug was hampered by reports of progressive multifocal leukoencephalopathy (PML) occuring in multiple...

  • Elan and Wyeth to take Alzheimer's drug to phase III.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p6 

    The article reports on the plan of Elan Corp. and Wyeth Pharmaceuticals to initiate a phase III clinical program for bapineuzumab, a humanized monoclonal antibody which is used to treat patients with mild to moderate Alzheimer's disease. According to the author, the move was based on a scheduled...

  • Elan/Wyeth unveil significant findings from phase IIa trial of AN-1792.  // PharmaWatch: CNS;September 2004, Vol. 3 Issue 9, p7 

    Reports on the findings of Elan Corp. and Wyeth Pharmaceuticals Inc.'s phase IIa clinical trial of an investigational Alzheimer's disease treatment drug, AN-1792. Beta amyloid immunotherapy approach; Use of an immunologic approach to clear beta amyloid from the brain; Evidence of beta amyloid...

  • Alzheimer's Disease Update.  // PharmaWatch: CNS;Aug2008, Vol. 7 Issue 8, p5 

    The article offers news briefs related to the pharmaceutical industry. Elan Corp. PLC and Wyeth have announced the positive preliminary findings of the Phase II study of bapineuzumab in patients with Alzheimer's disease. Myriad Genetics Inc. has also reported the results of the ActEarli-AD trial...

  • AD Attracts Huge Interest Despite Failures. Powers, Marie // BioWorld Today;8/27/2012, Vol. 23 Issue 166, p5 

    The article reports on the interest of several companies in developing drugs that could cure Alzheimer's disease despite failures in clinical trials, such as Johnson & Johnson, Pfizer Inc. and Elan Corp. PLC's bapineuzumab. Satori Pharmaceuticals is developing a class of oral gamma-secretase...

  • J&J-Pfizer's Alzheimer's Drug Crashes, Burns in Phase III. Sheridan, Cormac // BioWorld International;8/8/2012, Vol. 17 Issue 32, p1 

    The article reports on the failure of Pfizer Inc. and Johnson and Johnson's bapineuzumab to pass the Phase III trial in Alzheimer's disease. It notes that the antibody, which is discovered and developed by Elan Corp. PLC, has failed to meet the co-primary cognitive and functional performance...

  • Transition Slumps as Deaths End Higher Doses in AD Trial.  // BioWorld Today;12/16/2009, Vol. 20 Issue 241, p4 

    The article reports on the decline in the shares of Transition Therapeutics Inc. following disclosure that its Alzheimer's disease drug ELND005 lead to nine deaths, in December 2009. As stated, shares pegged at 3.50 U.S. dollars to close at 4.41 U.S. dollars. Information on the results from the...

  • New Alzheimer's Avenues In Targeting Of Amyloid, Tau. Breindl, Anette // BioWorld Today;5/23/2007, Vol. 18 Issue 100, p1 

    The article reports on the plan of Elan Corp. PLC and Wyeth to start phase III testing of bapineuzumab for the treatment of mild to moderate Alzheimer's disease. The drug targets amyloid beta. One of the cellular hallmarks of Alzheimer's disease is amyloid plaques or clumps of misfolded amyloid...

  • Myriad stumbles, Wyeth closes on Alzheimer's. Osborne, Randy // Nature Biotechnology;Aug2008, Vol. 26 Issue 8, p841 

    This article discusses efforts to develop medications for the treatment of Alzheimer's disease. Clinical trials of the human monoclonal antibody bapinezumab, under development by Wyeth, and the γ- and Β-secretase modulator Flurizan (R-flurbiprofin), under development by Myriad are...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics